NCT03516708View on ClinicalTrials.gov

Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

January 6, 2020

Primary Completion Date

July 15, 2027

Study Completion Date

August 12, 2030

Conditions
Rectal Cancer
Interventions
DRUG

Epacadostat

Drug provided.

RADIATION

Short-course radiation therapy

Short-course pelvic radiation therapy, 5 Gy x 5 fractions over 1 week

DRUG

CAPOX chemotherapy

Standard of care

DRUG

FOLFOX chemotherapy

Standard of care

Trial Locations (4)

48202

WITHDRAWN

Henry Ford Cancer Institute, Detroit

63110

RECRUITING

Washington University School of Medicine, St Louis

92868

WITHDRAWN

University of California Irvine - Chao Family Comprehensive Cancer Center, Orange

02215

RECRUITING

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Incyte Corporation
All Listed Sponsors
collaborator

Incyte Corporation

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Washington University School of Medicine

OTHER